Amidst a surge in clinical studies delving into the transformative potential of psychedelic drugs, an intriguing paradox has emerged within the market dynamics – a notable disparity between the expanding realm of scientific exploration and the lagging valuations of companies operating in the psychedelic sector.
Republican Senators James Lankford (Oklahoma) and Pete Ricketts (Nebraska) have introduced a bill that seeks…
New blue hues and flavors from top breeders have arrived. The post New Blueberry weed…
While there are many studies showing potential and promise for using various compounds in cannabis…
Trump's declaration of drug cartels as terrorist organizations and his war cry to ramp up…
A recent poll conducted by the University of Houston’s Hobby School of Public Affairs has…
Candies, Z, OGs, and more from Leafly’s senior editor. The post David Downs’ sickest weed…